Loading data for SRRK — first visit, this takes a few seconds.

알림

Scholar Rock (SRRK)

NasdaqGS: SRRK · 실시간 가격 · USD

58.25

+0.05 (0.09%)

종가 기준: Aug 25, 2026, 8:00 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.09% (1D)

데이터 없음

매수호가	42.5
시가총액	7.09B
매출 (ttm)	n/a
순이익 (ttm)	-408.59M
	0.67
	-3.31
	n/a
	-25.02
P/B (ttm)	27.91
P/S (ttm)	n/a
실적 발표일	Nov 12, 2026

매도호가	74.53
거래량	1,207,539
평균 거래량 (20일)	1,323,496
시가	58.20
전일 종가	58.20
일중 범위	57.06 - 59.48
52주 범위	27.07 - 59.48
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

SRRK 소개

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 25, 2018

직원 수 289

상장 거래소 NasdaqGS

티커 SRRK

웹사이트 https://www.scholarrock.com

전체 기업 정보

재무 실적

2025년 Scholar Rock의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -377.94M로, 53.45% 증가했습니다.

재무제표

어닝 서프라이즈

Scholar Rock가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.84 예상치 하회 0.00, 및 14.29% 전년 대비 성장.

다음 실적 발표

Scholar Rock의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

4일 전 · Simply Wall St.

Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns

Scholar Rock Holding stock has delivered an extremely strong multi year return, yet the latest valuation checks suggest the current share price may already be baking in a lot of optimism. After such a...

4일 전 · Simply Wall St.

Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?

Scholar Rock Holding (SRRK) updated investors after shifting apitegromab’s commercial fill finish work away from Catalent Indiana following FDA inspection issues, while confirming that the FDA is cont...

5일 전 · Simply Wall St.

Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?

Earlier this week, Scholar Rock announced it has removed Catalent Indiana from all commercial fill-finish roles for apitegromab, with the FDA continuing to review its U.S. BLA using an alternate, prev...

5일 전 · Stocktwits

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing

The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by Novo Nordisk—from its U.S. biologics license application for apitegromab.

5일 전 · MT Newswires

Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility

Scholar Rock (SRRK) said Friday that, under guidance from the FDA, it has removed Novo Nordisk's (NV

2 페이지 중 1

Scholar Rock (SRRK)